Health ❯ Patient Safety

Adverse Reactions

Clinical Trials Drug Complications Reporting Systems Medical Complications Sedation Practices Compensation Medical Emergencies

Novartis Moves to File Oral MS Drug After Phase‑3 Win as Separate CAR‑T Trials Are Paused

Remibrutinib’s superior late‑stage results open a regulatory path for a new oral therapy for relapsing MS.

Mayim Bialik Says One Low Dose of GLP‑1 Triggered Weeks of Severe Gastrointestinal Illness